A. Oliver Sartor, MD | Authors

December 28, 2021

A. Oliver Sartor, MD, discussen treatment options for PARP inhibitor use in patients with prostate cancer.

October 22, 2021

A specialist describes the advances being made in metastatic prostate cancer and provides some clinical pearls for community oncologists.

October 22, 2021

Oliver Sartor, MD, discusses the use of rucaparib in treating metastatic prostate cancer.

October 22, 2021

A key opinion leader explains the role of PARP inhibitors in metastatic prostate cancer and reviews clinical trial data.

October 22, 2021

Dr. Oliver Sartor illustrates the systemic treatment options for metastatic castration-resistant prostate cancer and what to consider when choosing therapies.

October 15, 2021

An expert oncologist discusses the biomarker testing targets in metastatic prostate cancer.

October 15, 2021

Oliver Sartor, MD, describes the different tests routinely ordered for metastatic prostate cancer.

June 01, 2016

In this interview ahead of the 2016 ASCO Annual Meeting we discuss some of the prostate cancer trials to watch out.

July 15, 2015

This article will describe the historic background of Ra-223; outline the clinical studies which led to phase III trials of this agent; highlight key results of these phase III studies; and explore possible future directions for use of Ra-223 and other alpha particles-both in prostate cancer and for management of other diseases.

June 15, 2013

In my experience, being treated for low-volume Gleason 6 tumors is the norm, not the exception, for men in the United States. Surveillance may be discussed as an option, but it is not taken seriously.